This move is archived. Current quotes and coverage live on the stock page.
Follow MDNA
Medicenna Therapeutics Corp experienced a notable gain in its stock price, reflecting positive investor sentiment.
In yesterday's trading session, Medicenna Therapeutics Corp (MDNA.TO) saw its stock price increase by 8.05%, closing at CA$0.47. This surge follows the company's recent announcement of a public offering, which has attracted investor interest.
Advertisement
Medicenna Therapeutics Corp
MDNA.TO
MDNA.TO
Medicenna Therapeutics Corp
WealthAwesomeMarket cap
$37.84M
52W high
$1.97
52W low
$0.34
1W change
-6.82%
Beta
2.10
Analyst Price Targets
Based on analyst covering MDNA · as of Sep 17, 2026
Wall Street analysts forecast MDNA stock price to rise 680.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.20
+680.5% Upside
Current Price
C$0.41
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on MDNA's historical volatility
30-Day Vol
53.4%
Annualized
90-Day Vol
53.2%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$0.50
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$0.45 | C$0.37 – C$0.54 |
| 60 trading days | C$0.47 | C$0.36 – C$0.61 |
| 90 trading days | C$0.50 | C$0.36 – C$0.69 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: The recent uptick in Medicenna's stock price may signal growing confidence in the company's strategic moves and potential for future growth, especially after its successful fundraising efforts.
Medicenna's stock rose by 8.05% yesterday.
The market cap of Medicenna Therapeutics Corp is approximately CA$43.38 million, indicating a small-cap status that can be subject to volatility.
Bull case
Investors might see the successful closing of the CDN$4.44 million public offering as a strong sign of Medicenna's financial health and its commitment to advancing its lead programs. This could lead to further appreciation in the stock price.
Bear case
Despite the positive movement, it's important for investors to stay cautious. The company has yet to report profitability, and its ongoing reliance on public offerings could raise concerns about long-term sustainability.
Advertisement
Public Offering Boosts Investor Confidence
Medicenna recently announced the closing of a public offering that raised approximately CDN$4.44 million. This capital will support the company's lead programs, which may have contributed to the positive sentiment surrounding the stock. Investors often react favorably to successful fundraising efforts, viewing them as a sign of potential growth.
Market Response and Future Outlook
The 8.05% increase in Medicenna's stock price reflects a broader market response to its strategic initiatives. While the surge is encouraging, investors should keep an eye on the company's ongoing financial performance and clinical developments to assess long-term viability. The small-cap nature of Medicenna's stock means it could be more susceptible to market fluctuations.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
